# Biogen Inc. (BIIB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $220.83, market value $32.6 billion.

## Valuation
- **P/E (trailing): 39.2×** (5-yr avg 20.5×, 3-yr avg 22.1×). Biogen Inc. trades at 39.2× trailing earnings, well above its own five-year average of 20.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.3×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 3.3×**. Each dollar of revenue is priced at 3.3×.
- **Price / book: 1.7×**. The shares trade at 1.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 8.0%** (5-yr avg 7.1%). Free cash flow equals 8.0% of the market value, in line with its five-year average of 7.1%. Above 5% is generally attractive.
- **Earnings yield: 2.5%**. The inverse of the P/E: 2.5% of the price is earned each year.

## Profitability
- **Net margin: 13.1%**. 13.1% of each dollar of sales reaches the bottom line.
- **Return on equity: 7.1%**. 7.1% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: 2.8%**. Each dollar of assets produces 2.8% of profit.

## Growth
- **Revenue growth (1 yr): 2.2%** (3-yr -0.9%/yr, 5-yr -6.0%/yr). Revenue grew 2.2% over the last year, against -6.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -21.4%** (3-yr -25.0%/yr, 5-yr -18.7%/yr). Earnings per share fell 21.4%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 21.5%/yr**. Free cash flow has compounded at 21.5% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.34**. Debt is 0.34 times equity: a conservative balance sheet.
- **Current ratio: 2.68** (quick 2.68). Current assets cover the next year's liabilities 2.68 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Biogen Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (31 analysts). 31 analysts cover Biogen Inc.; the consensus is buy, with an average price target of $236.22 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 57.8%** (YTD 25.5%, 3-mo 13.0%). The shares are up 57.8% over twelve months including dividends.
- **From 52-week high: -2.2%** (63.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 0.33** (volatility 35%). Beta of 0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BIIB · Page: https://foliofundamentals.com/stocks/biib

Not investment advice.